PortalPublikationenSplenic irradiation before hematopoietic stem cell transplan...

Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study

Standard

Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study. / Gratwohl, Alois; Iacobelli, Simona; Bootsman, Natalia; van Biezen, Anja; Baldomero, Helen; Arcese, William; Arnold, Renate; Bron, Dominique; Cordonnier, Catherine; Ernst, Peter; Ferrant, Augustin; Frassoni, Francesco; Gahrton, Gösta; Richard, Carlos; Kolb, Hans Jochem; Link, Hartmut; Niederwieser, Dietger; Ruutu, Tapani; Schattenberg, Anton; Schmitz, Norbert; Torres-Gomez, Antonio; Zwaan, Ferry; Apperley, Jane; Olavarria, Eduardo; Kröger, Nicolaus; Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

in: ANN HEMATOL, Jahrgang 95, Nr. 6, 05.2016, S. 967-72.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Gratwohl, A, Iacobelli, S, Bootsman, N, van Biezen, A, Baldomero, H, Arcese, W, Arnold, R, Bron, D, Cordonnier, C, Ernst, P, Ferrant, A, Frassoni, F, Gahrton, G, Richard, C, Kolb, HJ, Link, H, Niederwieser, D, Ruutu, T, Schattenberg, A, Schmitz, N, Torres-Gomez, A, Zwaan, F, Apperley, J, Olavarria, E, Kröger, N & Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT) 2016, 'Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study', ANN HEMATOL, Jg. 95, Nr. 6, S. 967-72. https://doi.org/10.1007/s00277-016-2638-6

APA

Gratwohl, A., Iacobelli, S., Bootsman, N., van Biezen, A., Baldomero, H., Arcese, W., Arnold, R., Bron, D., Cordonnier, C., Ernst, P., Ferrant, A., Frassoni, F., Gahrton, G., Richard, C., Kolb, H. J., Link, H., Niederwieser, D., Ruutu, T., Schattenberg, A., ... Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (2016). Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study. ANN HEMATOL, 95(6), 967-72. https://doi.org/10.1007/s00277-016-2638-6

Vancouver

Gratwohl A, Iacobelli S, Bootsman N, van Biezen A, Baldomero H, Arcese W et al. Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study. ANN HEMATOL. 2016 Mai;95(6):967-72. https://doi.org/10.1007/s00277-016-2638-6

Bibtex

@article{ebe2eda1b05f4747b6d12285a8bd04c8,
title = "Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study",
abstract = "In the context of discussions on the reproducibility of clinical studies, we reanalyzed a prospective randomized study on the role of splenic irradiation as adjunct to the conditioning for hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML). Between 1986 and 1989, a total of 229 patients with CML were randomized; of these, 225 (98 %; 112 with, 113 without splenic irradiation) could be identified in the database and their survival updated. Results confirmed the early findings with no significant differences in all measured endpoints (overall survival at 25 years: 42.7 %, 32.0-52.4 % vs 52.9 %, 43.2-62.6 %; p = 0.355, log rank test). Additional splenic irradiation failed to reduce relapse incidence. It did not increase non-relapse mortality nor the risk of late secondary malignancies. Comforting are the long-term results from this predefined consecutive cohort of patients: more than 60 % were alive at plus 25 years when they were transplanted with a low European Society for Blood and Marrow Transplantation (EBMT) risk sore. This needs to be considered today when treatment options are discussed for patients who failed initial tyrosine kinase inhibitor therapy and have an available low risk HLA-identical donor.",
keywords = "Adolescent, Adult, Child, Cohort Studies, Female, Follow-Up Studies, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Male, Middle Aged, Prospective Studies, Spleen, Time Factors, Transplantation Conditioning, Young Adult, Journal Article, Randomized Controlled Trial",
author = "Alois Gratwohl and Simona Iacobelli and Natalia Bootsman and {van Biezen}, Anja and Helen Baldomero and William Arcese and Renate Arnold and Dominique Bron and Catherine Cordonnier and Peter Ernst and Augustin Ferrant and Francesco Frassoni and G{\"o}sta Gahrton and Carlos Richard and Kolb, {Hans Jochem} and Hartmut Link and Dietger Niederwieser and Tapani Ruutu and Anton Schattenberg and Norbert Schmitz and Antonio Torres-Gomez and Ferry Zwaan and Jane Apperley and Eduardo Olavarria and Nicolaus Kr{\"o}ger and {Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT)}",
year = "2016",
month = may,
doi = "10.1007/s00277-016-2638-6",
language = "English",
volume = "95",
pages = "967--72",
journal = "ANN HEMATOL",
issn = "0939-5555",
publisher = "Springer",
number = "6",

}

RIS

TY - JOUR

T1 - Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study

AU - Gratwohl, Alois

AU - Iacobelli, Simona

AU - Bootsman, Natalia

AU - van Biezen, Anja

AU - Baldomero, Helen

AU - Arcese, William

AU - Arnold, Renate

AU - Bron, Dominique

AU - Cordonnier, Catherine

AU - Ernst, Peter

AU - Ferrant, Augustin

AU - Frassoni, Francesco

AU - Gahrton, Gösta

AU - Richard, Carlos

AU - Kolb, Hans Jochem

AU - Link, Hartmut

AU - Niederwieser, Dietger

AU - Ruutu, Tapani

AU - Schattenberg, Anton

AU - Schmitz, Norbert

AU - Torres-Gomez, Antonio

AU - Zwaan, Ferry

AU - Apperley, Jane

AU - Olavarria, Eduardo

AU - Kröger, Nicolaus

AU - Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

PY - 2016/5

Y1 - 2016/5

N2 - In the context of discussions on the reproducibility of clinical studies, we reanalyzed a prospective randomized study on the role of splenic irradiation as adjunct to the conditioning for hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML). Between 1986 and 1989, a total of 229 patients with CML were randomized; of these, 225 (98 %; 112 with, 113 without splenic irradiation) could be identified in the database and their survival updated. Results confirmed the early findings with no significant differences in all measured endpoints (overall survival at 25 years: 42.7 %, 32.0-52.4 % vs 52.9 %, 43.2-62.6 %; p = 0.355, log rank test). Additional splenic irradiation failed to reduce relapse incidence. It did not increase non-relapse mortality nor the risk of late secondary malignancies. Comforting are the long-term results from this predefined consecutive cohort of patients: more than 60 % were alive at plus 25 years when they were transplanted with a low European Society for Blood and Marrow Transplantation (EBMT) risk sore. This needs to be considered today when treatment options are discussed for patients who failed initial tyrosine kinase inhibitor therapy and have an available low risk HLA-identical donor.

AB - In the context of discussions on the reproducibility of clinical studies, we reanalyzed a prospective randomized study on the role of splenic irradiation as adjunct to the conditioning for hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML). Between 1986 and 1989, a total of 229 patients with CML were randomized; of these, 225 (98 %; 112 with, 113 without splenic irradiation) could be identified in the database and their survival updated. Results confirmed the early findings with no significant differences in all measured endpoints (overall survival at 25 years: 42.7 %, 32.0-52.4 % vs 52.9 %, 43.2-62.6 %; p = 0.355, log rank test). Additional splenic irradiation failed to reduce relapse incidence. It did not increase non-relapse mortality nor the risk of late secondary malignancies. Comforting are the long-term results from this predefined consecutive cohort of patients: more than 60 % were alive at plus 25 years when they were transplanted with a low European Society for Blood and Marrow Transplantation (EBMT) risk sore. This needs to be considered today when treatment options are discussed for patients who failed initial tyrosine kinase inhibitor therapy and have an available low risk HLA-identical donor.

KW - Adolescent

KW - Adult

KW - Child

KW - Cohort Studies

KW - Female

KW - Follow-Up Studies

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Leukemia, Myelogenous, Chronic, BCR-ABL Positive

KW - Male

KW - Middle Aged

KW - Prospective Studies

KW - Spleen

KW - Time Factors

KW - Transplantation Conditioning

KW - Young Adult

KW - Journal Article

KW - Randomized Controlled Trial

U2 - 10.1007/s00277-016-2638-6

DO - 10.1007/s00277-016-2638-6

M3 - SCORING: Journal article

C2 - 26994010

VL - 95

SP - 967

EP - 972

JO - ANN HEMATOL

JF - ANN HEMATOL

SN - 0939-5555

IS - 6

ER -